Premium
Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas
Author(s) -
Pavel Marianne E.,
Hassler Gerda,
Baum Ulrich,
Hahn Eckhart G.,
Lohmann Tobias,
Schuppan Detlef
Publication year - 2005
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2005.02238.x
Subject(s) - angiogenin , chromogranin a , angiogenesis , medicine , cytokine , vascular endothelial growth factor , basic fibroblast growth factor , neuroendocrine tumors , carcinoma , growth factor , endocrinology , oncology , vegf receptors , immunohistochemistry , receptor
Summary Objective The growth behaviour of well‐differentiated neuroendocrine carcinomas of the gastro‐entero‐pancreatic system varies greatly and parameters predicting their prognosis are lacking. The aim of our study was to investigate whether tumour growth could be correlated with the release of proangiogenic factors into the circulation. Patients and methods Circulating vascular endothelial growth factor (VEGF), interleukin‐8 (IL‐8), basic fibroblast growth factor (bFGF) and angiogenin were measured in 38 patients with advanced neuroendocrine carcinomas and compared to healthy age‐matched controls. In 20 patients, angiogenic cytokine levels were measured at consecutive time points and correlated to tumour progression as assessed by abdominal CT scan, MRI and chromogranin A levels. Results VEGF levels were elevated in patients compared to controls ( P < 0·002) and clearly associated with tumour progression ( P < 0·005). Angiogenin levels were significantly higher in patients than in controls ( P < 0·003), while high IL‐8 levels were predictive of shorter survival. Angiogenin and bFGF levels were correlated neither with tumour growth nor with patient survival. Conclusions VEGF and IL‐8 are associated with tumour progression and might qualify as markers of prognosis and therapy control in patients with neuroendocrine carcinomas. Our results support the notion that specific anti‐angiogenic therapies should be evaluated in neuroendocrine carcinoma patients.